Dawn Maier, MSc
Senior Director, Process Development
Dawn Maier MSc, is responsible for leading the process development and manufacturing teams. In addition, she works closely with the scientific and business development executive staff to evaluate product opportunities and lead the CMC strategic planning for next generation industrial best practices.
Dawn has over 20 years of research and GMP experience in multiple scientific disciplines, with 15 years working in the cell and gene therapy field. She began her career in 2002 and spent 4 years at Thomas Jefferson University studying HIV and utilizing the SV40 virus for gene delivery. In 2007 she spent 6 years working for Bruce Levine within the Clinical Cell and Vaccine Production Facility (CVPF) at University of Pennsylvania, Abramson Cancer Center, where she focused on the translation and development of multiple novel manufacturing platforms in support of > 15 diverse early Phase I/II programs. In 2013, she joined bluebird bio and was responsible for building out their process development capabilities as well as leading the teams in the development and tech transfer of the bb2121 CAR T product in oncology and Lenti-D and Lenti-G products for ALD, Beta Thal and Sickle cell disease. She spent 4.5 years at bluebird bio before moving on to lead the process and analytical development teams at Unum Therapeutics, where she was responsible for development of their ACTR (antibody coupled T cell receptor) technologies. While at Unum she not only led the cellular process development but also led the viral process development and analytical development teams.